Coronavirus (COVID-19) Update: FDA Limits Use of Certain Monoclonal Antibodies to Treat COVID-19 Due to the Omicron Variant
The FDA revised the authorizations for two monoclonal antibody treatments to limit their use due to the omicron variant.
Coco Valjean mark this message contains misinformation
｜originally written by Coco Valjean
世界上並沒有單株抗體叫做Bebtelevimb，但是文中提到的禮來藥廠，確實有生產一種複合單株抗體Bamlanivimab + etesevimab，可能作者不懂將這兩個字二合一，創造出Bebtelevimb這名詞。
而真正的Bamlanivimab + etesevimab，在今年一月已經被美國FDA公告對Omicron效果不大，列為限制性使用，文中竟然稱這是對Omicron唯一有效且輕症也要注射！！！
而真正的Bamlanivimab + etesevimab，在今年一月已經被美國FDA公告對Omicron效果不大，列為限制性使用，文中竟然稱這是對Omicron唯一有效且輕症也要注射！！！
References
https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-limits-use-certain-monoclonal-antibodies-treat-covid-19-due-omicronhttps://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-limits-use-certain-monoclonal-antibodies-treat-covid-19-due-omicron
The content above by Cofacts message reporting chatbot and crowd-sourced fact-checking community is licensed under Creative Commons Attribution-ShareAlike 4.0 (CC BY-SA 4.0), the community name and the provenance link for each item shall be fully cited for further reproduction or redistribution.